6-Methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)phenyl]methyl]-2,3-dihydroinden-1-one

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 6-Methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)phenyl]methyl]-2,3-dihydroinden-1-one
• 英文别名: 6-methoxy-5-morpholin-4-yl-2-[[3-(trifluoromethyl)phenyl]methyl]-2,3-dihydroinden-1-one
• 化学式: C₂₂H₂₂F₃NO₃
• 分子量: 405.4
• InChiKey: FYPURVLMVKTZAS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  29
• 可旋转键数：
  4
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  38.8
• 氢给体数：
  0
• 氢受体数：
  7

文献信息

• Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor Antagonists for Treating Multiple Sclerosis
  申请人：Arrien Pharmaceuticals LLC

  公开号：US20150072980A1

  公开（公告）日：2015-03-12

  The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

  本发明涉及化合物、它们的合成以及它们作为Retinoic acid-related orphan核受体γt (RORγt)/RORγ的拮抗剂、逆向激动剂、调节剂和/或抑制剂的用途。本发明的化合物对调节RORγt)/RORγ活性以及治疗由RORγt)/RORγ介导的疾病或病况具有用处，例如与人类自身免疫疾病的免疫病理学相关的疾病状态，如多发性硬化症（MS）、类风湿关节炎（RA）、炎症性结肠炎、牛皮癣、慢性阻塞性肺病（COPD）、疼痛、肥胖、糖尿病、血脂异常、骨质疏松症、哮喘、神经退行性疾病和癌症。
• PROCESS FOR PREPARING SUBSTITUTED 2,3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS
  申请人：Arrien Pharmaceuticals LLC

  公开号：EP3680237A1

  公开（公告）日：2020-07-15

  The present invention is directed to the synthesis of compounds of formula (I) useful for modulating RORγt/RORγ activity and for treating diseases or conditions mediated by RORγt/RORγ and thus disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

  本发明涉及式 (I) 化合物的合成，该化合物可用于调节 RORγt/RORγ 活性，治疗由 RORγt/RORγ 介导的疾病或病症，从而治疗与人类自身免疫性疾病免疫病理相关的疾病状态，如多发性硬化症 (MS)、类风湿性关节炎 (RA)、炎症性结肠炎、牛皮癣、慢性阻塞性肺病、疼痛、肥胖、糖尿病、血脂异常、骨质疏松症、哮喘、神经退行性疾病和癌症。
• Substituted 2,3-dihydro-1H-inden-1-one Retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
  申请人：Arrien Pharmaceuticals LLC

  公开号：US10172866B2

  公开（公告）日：2019-01-08

  The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

  本发明涉及化合物、其合成及其作为视黄酸相关孤儿核受体γt（RORγt）/RORγ的拮抗剂、逆激动剂、调节剂和或抑制剂的用途。本发明的化合物可用于调节 RORγt)/RORγ 的活性，治疗由 RORγt)/RORγ 介导的疾病或病症，例如与人类自身免疫性疾病的免疫病理相关的疾病状态，如多发性硬化症 (MS)、类风湿性关节炎 (RA)、炎症性结肠炎、牛皮癣、慢性阻塞性肺病、疼痛、肥胖、糖尿病、血脂异常、骨质疏松症、哮喘、神经退行性疾病和癌症。
• Substituted 2, 3-dihydro-1H-inden-1-one retinoic acid-related orphan nuclear receptor antagonists for treating multiple sclerosis
  申请人：Arrien Pharmaceuticals LLC

  公开号：US10682358B2

  公开（公告）日：2020-06-16

  The present invention is directed to compounds, their synthesis, and their use as antagonists, inverse agonists, modulators and or inhibitors of the Retinoic acid-related orphan nuclear receptor γt (RORγt)/RORγ. The compounds of the present invention are useful for modulating RORγt)/RORγ activity and for treating diseases or conditions mediated by RORγt)/RORγ such as for example, disease states associated with immunopathology of human autoimmune diseases such as Multiple Sclerosis (MS), Rheumatoid Arthritis (RA), Inflammatory Colitis, Psoriasis, COPD, Pain, Obesity, Diabetes, Dyslipidemia, Osteoporosis, Asthma, Neurodegenerative diseases and Cancer.

  本发明涉及化合物、其合成及其作为视黄酸相关孤儿核受体γt（RORγt）/RORγ的拮抗剂、逆激动剂、调节剂和或抑制剂的用途。本发明的化合物可用于调节 RORγt)/RORγ 的活性，治疗由 RORγt)/RORγ 介导的疾病或病症，例如与人类自身免疫性疾病的免疫病理相关的疾病状态，如多发性硬化症 (MS)、类风湿性关节炎 (RA)、炎症性结肠炎、牛皮癣、慢性阻塞性肺病、疼痛、肥胖、糖尿病、血脂异常、骨质疏松症、哮喘、神经退行性疾病和癌症。
• SUBSTITUTED 2, 3-DIHYDRO-1H-INDEN-1-ONE RETINOIC ACID-RELATED ORPHAN NUCLEAR RECEPTOR ANTAGONISTS FOR TREATING MULTIPLE SCLEROSIS
  申请人：Arrien Pharmaceuticals LLC

  公开号：EP3044223A2

  公开（公告）日：2016-07-20